GAMMA Investing LLC Acquires 332,105 Shares of Sanofi (NASDAQ:SNY)

GAMMA Investing LLC increased its position in Sanofi (NASDAQ:SNY - Free Report) by 8,703.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 335,921 shares of the company's stock after purchasing an additional 332,105 shares during the quarter. GAMMA Investing LLC's holdings in Sanofi were worth $18,630,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in SNY. McClarren Financial Advisors Inc. lifted its stake in shares of Sanofi by 952.6% in the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock valued at $28,000 after purchasing an additional 543 shares during the period. Bessemer Group Inc. lifted its stake in Sanofi by 59.8% in the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company's stock valued at $32,000 after buying an additional 242 shares during the period. Lee Danner & Bass Inc. acquired a new position in Sanofi in the fourth quarter valued at about $31,000. Sierra Ocean LLC bought a new position in Sanofi during the fourth quarter worth about $44,000. Finally, Whipplewood Advisors LLC acquired a new position in shares of Sanofi during the 4th quarter worth about $76,000. 14.04% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

SNY has been the topic of a number of analyst reports. The Goldman Sachs Group started coverage on shares of Sanofi in a research report on Friday, March 21st. They issued a "neutral" rating and a $65.00 price target on the stock. Hsbc Global Res raised shares of Sanofi to a "strong-buy" rating in a research report on Monday, April 28th. Morgan Stanley set a $56.00 price target on shares of Sanofi in a report on Monday, June 2nd. BNP Paribas began coverage on Sanofi in a research note on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price objective on the stock. Finally, Guggenheim reiterated a "buy" rating on shares of Sanofi in a report on Tuesday. Three research analysts have rated the stock with a hold rating, three have issued a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Sanofi has an average rating of "Buy" and an average price target of $61.50.

Sanofi Stock Up 1.4%

Shares of SNY stock traded up $0.71 during trading hours on Friday, hitting $50.47. 1,737,422 shares of the company were exchanged, compared to its average volume of 2,410,139. Sanofi has a 52 week low of $45.80 and a 52 week high of $60.12. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. The business has a 50 day moving average of $51.71 and a two-hundred day moving average of $51.95. The company has a market capitalization of $123.78 billion, a PE ratio of 20.27, a PEG ratio of 1.01 and a beta of 0.50.

Sanofi (NASDAQ:SNY - Get Free Report) last released its earnings results on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. The firm had revenue of $10.41 billion during the quarter, compared to analysts' expectations of $9.79 billion. During the same quarter in the prior year, the company earned $1.78 EPS. The company's revenue was down 11.0% on a year-over-year basis. Analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Thursday, June 12th. Investors of record on Friday, May 9th will be issued a dividend of $2.0369 per share. The ex-dividend date of this dividend is Friday, May 9th. This is an increase from Sanofi's previous annual dividend of $1.48. This represents a dividend yield of 3.1%. Sanofi's dividend payout ratio (DPR) is presently 57.14%.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.